Skip to main content
Premium Trial:

Request an Annual Quote

Progenetics to Distribute Biocept's Liquid Biopsy Assays in Israel

NEW YORK (GenomeWeb) – Biocept announced today that cancer genomics firm Progenetics will market and distribute its complete portfolio of Target Selector liquid biopsy assays in Israel. Other terms of the agreement were not disclosed.

Progenetics, founded in 2014 and based in Tel Aviv, Israel, provides advanced tumor profiling services. Last July, it signed an agreement with OncoDNA to provide Israeli physicians with a variety of other cancer tests.

According to its website, Progenetics also has testing collaborations with the Mayo Clinic, Quest Diagnostics, Response Genetics, BioReference Laboratories, NeoGenomics Laboratories, Adaptive Biotechnologies, and Otogenetics.

Raaj Trivedi, Biocept's vice president of commercial operations, said in a statement that the company sees its new agreement with Progenetics as a "model for additional agreements with distributors in select global markets."